Krüppel-like factor 4 downregulation during esophageal cancer formation facilitates immune evasion and impairs immunotherapy

Area of Science:

• Cancer Immunology
• Molecular Oncology
• Immunotherapy

Background:

• Impaired antigen processing and presentation are key mechanisms of cancer immune evasion.
• The precise molecular regulators of these processes in cancer remain incompletely understood.
• Krüppel-like factor 4 (KLF4) has emerged as a potential player in cancer development and immune response.

Purpose of the Study:

• To investigate the role of Krüppel-like factor 4 (KLF4) in cancer immune evasion and antigen presentation.
• To elucidate the molecular mechanisms by which KLF4 influences MHC class I expression.
• To evaluate the therapeutic potential of modulating KLF4 for cancer immunotherapy.

Main Methods:

• Analysis of KLF4 expression in esophageal cancer tissues and correlation with clinical outcomes.
• Investigation of KLF4's effect on MHC class I expression and chromatin accessibility in cancer cells.
• Evaluation of KLF4 modulation on tumor progression, T cell infiltration, and immunotherapy response in mouse models.

Main Results:

• Suppressed KLF4 expression in esophageal cancer leads to diminished MHC class I production, creating an immunosuppressive tumor microenvironment that limits CD8+ T cell infiltration.
• KLF4 loss reduces chromatin accessibility at MHC class I loci, thereby suppressing its expression.
• Low KLF4 levels correlate with poor immunotherapy outcomes across various human cancers, and pharmacological KLF4 induction enhances antigen presentation and PD-1 blockade efficacy in mice.

Conclusions:

• KLF4 downregulation is a critical mechanism for cancer immune evasion by impairing antigen presentation and T cell responses.
• Targeting KLF4 represents a promising novel strategy to enhance cancer immunotherapy efficacy.
• Restoring KLF4 function can overcome immunotherapy resistance by improving the tumor's recognition by the immune system.